Compare BDSX & CDLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | CDLX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.0M | 69.7M |
| IPO Year | 2020 | 2018 |
| Metric | BDSX | CDLX |
|---|---|---|
| Price | $15.77 | $0.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $32.50 | $2.25 |
| AVG Volume (30 Days) | 127.3K | ★ 629.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $88,499,000.00 | ★ $278,298,000.00 |
| Revenue This Year | $22.01 | N/A |
| Revenue Next Year | $26.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.25 | $0.80 |
| 52 Week High | $17.40 | $3.28 |
| Indicator | BDSX | CDLX |
|---|---|---|
| Relative Strength Index (RSI) | 73.20 | 38.41 |
| Support Level | $6.33 | $0.83 |
| Resistance Level | N/A | $1.04 |
| Average True Range (ATR) | 1.71 | 0.09 |
| MACD | 0.29 | 0.00 |
| Stochastic Oscillator | 74.31 | 31.03 |
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.